Bolt Biotherapeutics (BOLT) EBT Margin (2020 - 2025)
Historic EBT Margin for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to 333.15%.
- Bolt Biotherapeutics' EBT Margin rose 9969100.0% to 333.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 824.54%, marking a year-over-year decrease of 1111800.0%. This contributed to the annual value of 881.57% for FY2024, which is 29900.0% down from last year.
- According to the latest figures from Q3 2025, Bolt Biotherapeutics' EBT Margin is 333.15%, which was up 9969100.0% from 477.33% recorded in Q2 2025.
- In the past 5 years, Bolt Biotherapeutics' EBT Margin registered a high of 293.63% during Q1 2024, and its lowest value of 5345.87% during Q4 2021.
- In the last 5 years, Bolt Biotherapeutics' EBT Margin had a median value of 1145.17% in 2023 and averaged 1508.48%.
- In the last 5 years, Bolt Biotherapeutics' EBT Margin skyrocketed by 39286400bps in 2022 and then plummeted by -6869800bps in 2024.
- Over the past 5 years, Bolt Biotherapeutics' EBT Margin (Quarter) stood at 5345.87% in 2021, then skyrocketed by 73bps to 1417.22% in 2022, then skyrocketed by 40bps to 857.01% in 2023, then tumbled by -55bps to 1330.06% in 2024, then surged by 75bps to 333.15% in 2025.
- Its EBT Margin was 333.15% in Q3 2025, compared to 477.33% in Q2 2025 and 905.24% in Q1 2025.